PF-Atlas › Clinical Trials › NCT05270668
Phase 2 Safety and Efficacy Study of Tulisokibart in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease
Tulisokibart · Phase 2
Registry ID
NCT05270668
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
Tulisokibart
Sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Start
2022-03-29
Enrollment
154
Locations
95
About this trial
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05270668 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.